safety concerns

Law firm Kahn Swick & Foti alleges Soleno Therapeutics failed to disclose material safety concerns with its flagship DCCR product, with lead plaintiff applications due May 5, 2026.

Class action lawsuit filed against $SLNO over alleged securities fraud tied to DCCR safety concerns, patient death, and disappointing Q3 results that triggered sharp stock declines.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.

Rosen Law Firm files securities class action against $SLNO for alleged misstatements regarding safety concerns with DCCR drug candidate for Prader-Willi syndrome treatment.

Soleno Therapeutics ($SLNO) faces securities fraud lawsuit over DCCR drug for Prader-Willi syndrome. Stock plunged following safety concerns, patient death, and weak Q3 results.

Schall Law Firm filed securities fraud class action against $SLNO for allegedly concealing safety concerns in Phase 3 DCCR trial. Investors eligible through November 4, 2025.

Soleno Therapeutics faces class action lawsuit alleging failure to disclose safety concerns about DCCR drug candidate from clinical trials.

Soleno Therapeutics faces class action lawsuit alleging material safety concerns about DCCR drug were hidden from investors. Lead plaintiff deadline is May 5, 2026.

Class action lawsuit filed against Soleno Therapeutics for allegedly failing to disclose material safety concerns about its DCCR product. Investors can apply as lead plaintiff by May 5, 2026.

Tesla's robotaxi fleet shows crash rates 4-8 times higher than human drivers, with only 42 vehicles operating. Regulatory challenges and high stock valuations intensify pressure on autonomous ambitions.